REG - HeiQ PLC - Notice of H1 2022 Results and Presentation

HeiqAnnouncement

30/08/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220830:nRSd4268Xa&default-theme=true

RNS Number : 4268X  HeiQ PLC  30 August 2022

30 August 2022

 

HeiQ Plc

("HeiQ" or "the Company")

 

Notice of H1 2022 Results and Presentation

 

HeiQ Plc (LSE: HEIQ), a Swiss IP innovator and established global brand in
materials and textile innovation which operates in high-growth markets, is
pleased to announce that its results for the six months ended 30 June 2022
("H1 2022") will be published on Tuesday 13 September 2022.

 

H1 2022 Trading Update

HeiQ is pleased to report that the Company is expecting to report revenue of
over US$30m for H1 2022, an increase of more than 17% compared to the six
months ended 30 June 2021 ("H1 2021") (US$25.8m). This growth has been
achieved despite the challenging macro-economic environment, including the
shutdown of key markets in China for over three months during the six-month
period. The Company expects to report gross profit margins for H1 2022 of
46.7%, an improvement from the levels seen in the second half of the 2021
financial year (43.7%). Whilst the increased cost of raw materials placed
pressure on margin during the period, pleasingly, the trend of margin
improvement is continuing into the second half of this financial year ("H2
2022"), as the benefit of passed on price increases materialise and raw
material costs start to stabilise.

 

HeiQ is pleased to report significant progress regarding the development of
its potential blockbuster technologies:

·    HeiQ successfully launched HeiQ AeoniQ, a high performance, climate
positive, cellulose yarn designed as a sustainable substitute for the US$135
billion Polyester and Nylon market.

·    Received investment from HUGO BOSS which provides an implied
valuation of US$200 million for the platform.

·    All contractual milestones with HUGO BOSS have been met, releasing
US$9 million contractual payments and the pilot commercialisation plant has
successfully commenced.

·    Tangible progress has also been achieved for its other potential
blockbuster technologies, HeiQ GrapheneX, with the validation of a solid state
batteries prototype at double energy capacity, and HeiQ Synbio recognised in a
peer reviewed publication by Europe's leading Hospital, Charité Berlin
confirming the potential to reduce Hospital Acquired Infections

HeiQ has demonstrated a resilient trading performance during H1 2022 and the
Directors remain optimistic that the Company will trade in-line with market
guidance for the full financial year, although, like all companies, the
Company is not immune from the impact of unforeseen global economic events and
raw material spikes.

 

Details of briefing for equity analysts

Carlo Centonze, CEO, and Xaver Hangartner, CFO will host a briefing for
analysts relating to its H1 2022 results for equity analysts at 09:30 a.m. BST
on Tuesday 13 September 2022. Any equity analysts wishing to attend or
register should contact SEC Newgate UK at HeiQ@secnewgate.co.uk
(mailto:HeiQ@secnewgate.co.uk) where further details will be provided.

 

Details of webinar for investors

The Company is also pleased to announce that Carlo
Centonze and Xaver Hangartner will provide a live presentation relating to
its H1 2022 results via the Investor Meet Company platform on Wednesday 14
September at 12:00 p.m. BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up
until 09:00 a.m. the day before the meeting or at any time during the live
presentation.

 

Investors can sign up to Investor Meet Company for free and add to
meet HeiQ Plc via:

 

https://www.investormeetcompany.com/heiq-plc/register-investor
(https://www.investormeetcompany.com/heiq-plc/register-investor)

 

Investors who have already registered and added to meet the Company will be
automatically invited.

 

For further information, please contact:

 

 HeiQ Plc                                                +41 56 250 68 50

 Carlo Centonze (CEO)
 Cenkos Securities plc (Joint Broker)                    +44 (0) 207 397 8900

 Stephen Keys / Callum Davidson
 SEC Newgate (Media Enquiries)                           +44 (0) 20 3757 6882

 Elisabeth Cowell / Axaule Shukanayeva / Molly Gretton   HeiQ@s (mailto:HeiQ@secnewgate.co.uk) ecnewgate (mailto:HeiQ@secnewgate.co.uk)
                                                         .co.uk (mailto:HeiQ@secnewgate.co.uk)

 

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by
innovating the materials people use every day. HeiQ has strong IP which is at
the forefront of global technology in the $10 billion antimicrobial fabrics
market, $24 billion textile chemicals market, the $50 billion probiotics
market and the $150 billion man-made fibers market. It has also moved into the
medical device, healthcare and hygiene coatings markets, to help make
hospitals and healthcare environments more hygienic. HeiQ aims to deliver
growth for its shareholders through a combination of increased sales of its
core products and by entering additional lucrative markets through disruptive
innovations and M&A.

HeiQ has created some of the most effective, durable and high-performance
technologies in the market today, which cool, warm, dry, repel, purify, and
destroy viruses. Since 2005, HeiQ has developed over 200 technologies in
partnership with 300 major brands and it has a significant R&D pipeline
containing over 50 projects. The Company has won multiple awards and gained a
strong reputation for the ESG & sustainable downstream effect of its
innovations. HeiQ is the only company to have won the Swiss Technology award
twice. It has also won the Swiss Environmental award with an innovation that
saves energy and water consumption during the textile manufacturing process.

Led by an experienced leadership team, HeiQ researches new solutions for
partners, delivers scaled up manufacturing from its sites across the world and
helps partners market the product to end consumers - aiming for lab to
consumer in months.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPFMITMTMTBPT